Top Growth Trends in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market: Insights into Market Size and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theNucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The growing prevalence of genetic disorders is expected to drive the expansion of the nucleic acid and gene therapies market in neuromuscular disorders. Genetic disorders are diseases caused by abnormalities in an individual’s DNA, either inherited or due to mutations. The rise in genetic disorders can be attributed to factors such as genetic mutations, environmental influences, lifestyle changes, and advancements in diagnostic capabilities. Nucleic acid and gene therapies address these disorders by correcting or replacing defective genes in neuromuscular conditions, restoring normal function. For instance, in May 2024, Cure SMA, a US-based non-profit organization, reported that approximately 9,000 to 9,500 people in the United States are living with Spinal Muscular Atrophy (SMA), with 37% having Type 2 SMA. The condition has an incidence rate of 1 in 15,000 births. As a result, the growing prevalence of genetic disorders is fueling the growth of the nucleic acid and gene therapies in neuromuscular disorders market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
#What Long-Term Growth Rate is Expected for theNucleic Acid And Gene Therapies In Neuromuscular Disorders Market Between 2025 and 2034?
The nucleic acid and gene therapies for neuromuscular disorders market has seen strong growth, increasing from $6.84 billion in 2024 to $7.52 billion in 2025 at a CAGR of 9.9%. Growth has been driven by an increase in regulatory approvals, rising demand for nucleic acid and gene therapies, the need for more precise treatments, and an increasing number of gene therapy-based discoveries.
The nucleic acid and gene therapies in neuromuscular disorders market is poised for strong growth, reaching $10.87 billion by 2029, with a CAGR of 9.7%. Growth is driven by a rising prevalence of genetic disorders, increasing R&D investments, growing demand for precision medicine, higher approval rates for gene therapy products, and an increasing burden of chronic conditions. Emerging trends include advancements in patient care, high-performance chromatography, innovative treatment solutions, gene editing technologies, and improved nucleic acid extraction technologies.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21233
What Are the Current Market Growth and Trends in theNucleic Acid And Gene Therapies In Neuromuscular Disorders Market That Industry Players Should Watch?
In the nucleic acid and gene therapies for neuromuscular disorders market, companies are focusing on gene therapy to address the genetic causes of neuromuscular conditions. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years. This therapy delivers a gene coding for a micro-dystrophin protein, which is essential for muscle function. The therapy offers a potential cure by addressing the underlying genetic defect, simplifying the treatment process with a single intravenous infusion, potentially halting or reversing disease progression in DMD patients.
What Are the Major Market Players Making an Impact on theNucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
Order Your Report Now For A Swift Delivery:
How Are the Key Segments of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Driving Opportunities and Innovations?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy
3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theNucleic Acid And Gene Therapies In Neuromuscular Disorders Market?# Market Expansion?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2025, By The Business Research Company:
Insulin Biosimilars Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
Insulin Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report
Blood Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
